Lipid Disorders
Conference Coverage
Fish oil pills do not reduce fractures in healthy seniors: VITAL
The largest worldwide study to examine how fish oil supplements might reduce the risk of fractures did not find any benefit.
Conference Coverage
Dietary change tops for reducing CVD risk in stage 1 hypertension
Healthy lifestyle changes, particularly adoption of the DASH diet, can reduce CVD events in people with stage 1 hypertension.
Commentary
When do we stop using BMI to diagnose obesity?
Before emotions hijack the conversation, let’s discuss BMI’s past, present, and future.
Feature
‘Spectacular’ polypill results also puzzle docs
“If they got the same results on the biomarkers that the pill was designed to intervene upon, why are the [primary outcome] results different? It’...
From the Journals
Test Lp(a) levels to inform ASCVD management: NLA statement
“The question in the scientific community is: What role does that particular biomarker play in terms of causing serious heart disease, stroke, and...
Conference Coverage
No invasive strategy benefit at 5 years in ISCHEMIA-CKD extension study
The trial speaks to the lofty high-risk status of patients with CAD. ‘You’re seeing in a group of patients, with largely preserved EF but advanced...
From the Journals
Artificial sweeteners linked to higher CV event risk
The first study to include artificial sweetener from all sources, not just drinks, may increase concerns about these agents. But not all are...
Latest News
Candy, desserts: A ‘gateway’ to unhealthy eating among teens
Over the past 30 years, there’s been a steady increase in consumption of ultra-processed foods worldwide, coupled with mounting evidence that...
Opinion
Muscling through the data
Sometimes no amount of solid data will change the mind of someone who’s already made theirs up.
Conference Coverage
Majority of muscle symptoms with statins not caused by treatment
A new Cholesterol Trialists Collaboration meta-analysis shows that in 14 of the 15 people who experience muscle pain or weakness when taking a...
Conference Coverage
Evolocumab benefits accrue with longer follow-up: FOURIER OLE
Chief among the benefits was a reduction in cardiovascular mortality not observed in the pivotal trial that led to U.S. approval of evolocumab.